HomeCompareMVRBF vs BTI

MVRBF vs BTI: Dividend Comparison 2026

MVRBF yields 243.90% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MVRBF wins by $394.58M in total portfolio value
10 years
MVRBF
MVRBF
● Live price
243.90%
Share price
$0.82
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$394.62M
Annual income
$218,439,906.42
Full MVRBF calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — MVRBF vs BTI

📍 MVRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMVRBFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MVRBF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MVRBF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVRBF
Annual income on $10K today (after 15% tax)
$20,731.71/yr
After 10yr DRIP, annual income (after tax)
$185,673,920.46/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, MVRBF beats the other by $185,671,538.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVRBF + BTI for your $10,000?

MVRBF: 50%BTI: 50%
100% BTI50/50100% MVRBF
Portfolio after 10yr
$197.33M
Annual income
$109,221,354.35/yr
Blended yield
55.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

MVRBF
No analyst data
Altman Z
1.7
Piotroski
0/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVRBF buys
0
BTI buys
0
No recent congressional trades found for MVRBF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMVRBFBTI
Forward yield243.90%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$394.62M$37.8K
Annual income after 10y$218,439,906.42$2,802.29
Total dividends collected$375.65M$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: MVRBF vs BTI ($10,000, DRIP)

YearMVRBF PortfolioMVRBF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$35,090$24,390.24$11,301$601.08+$23.8KMVRBF
2$117,533$79,986.88$12,799$706.58+$104.7KMVRBF
3$376,147$250,386.00$14,527$832.38+$361.6KMVRBF
4$1,151,374$748,897.11$16,527$982.75+$1.13MMVRBF
5$3,374,355$2,142,384.97$18,846$1,162.95+$3.36MMVRBF
6$9,478,533$5,867,972.46$21,545$1,379.49+$9.46MMVRBF
7$25,546,778$15,404,747.63$24,694$1,640.41+$25.52MMVRBF
8$66,138,099$38,803,046.68$28,378$1,955.69+$66.11MMVRBF
9$164,653,072$93,885,306.32$32,702$2,337.79+$164.62MMVRBF
10$394,618,693$218,439,906.42$37,794$2,802.29+$394.58MMVRBF

MVRBF vs BTI: Complete Analysis 2026

MVRBFStock

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Full MVRBF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this MVRBF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVRBF vs SCHDMVRBF vs JEPIMVRBF vs OMVRBF vs KOMVRBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.